Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
87 results about "Pancreatic tumor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The pancreatic tumors (or pancreatic neoplasms) are tumors arising in the pancreas. There are several types, which can be either benign or malignant (pancreatic cancer).
Glucocorticoid receptor modulators to treat pancreatic cancer
ActiveUS9943505B2Reduce loadHalogenated hydrocarbon active ingredientsHeavy metal active ingredientsTumor LoadMedicine
Owner:CORCEPT THERAPEUTICS INC
Molecules that home to various selected organs or tissues
InactiveUS6933281B2NanotechCell receptors/surface-antigens/surface-determinantsAbnormal tissue growthWilms' tumor
The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.
Owner:THE BURNHAM INST
Angiogenic agents from plant extracts, gallic acid, and derivatives
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE +1
Treatments for cancer
ActiveUS20080206256A1Microbiological testing/measurementGenetic material ingredientsAbnormal tissue growthLymphatic Spread
The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents.
Owner:FIBROGEN INC
Custom Vectors for Treating and Preventing Pancreatic Cancer
ActiveUS20080166367A1Improve abilitiesPreventing and delaying onsetSugar derivativesGenetic material ingredientsAntigenOncology
The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
Owner:REPRESENTED BY THE SEC DEPT OF HEALTH & HUMAN SERVICES +1
Molecules that home to various selected organs or tissues
The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.
Owner:THE BURNHAM INST
Method and kit for biopsying of pancreatic tumor masses
InactiveUS20070123799A1Rapid, erosive and relatively non-invasiveSurgeryVaccination/ovulation diagnosticsPancreatic tumorStandard procedure
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Pancreatic tumour treatment
InactiveUS20110293672A1Significant systemic toxicityImprove the level ofBiocidePowder deliveryWater basedMicrosphere
There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition.
Owner:BIOCOMPATIBLES UK LTD
Glucocorticoid receptor modulators to treat pancreatic cancer
ActiveUS20180071255A1Reduce tumor loadReduce loadHeavy metal active ingredientsHalogenated hydrocarbon active ingredientsMedicineGlucocorticoid receptor
Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.
Owner:CORCEPT THERAPEUTICS INC
Application of Glypican-1 protein in diagnosis of pancreatic cancer, detection method of positive exosome concentration, and use of detection method
InactiveCN106950374AServe as a diagnosisPlay the role of staging judgment, etc.Raman scatteringBlood plasmaBiology
The invention discloses an application of a Glypican-1 protein in the diagnosis of pancreatic cancer, a detection method of a Glypican-1 positive exosome concentration, and a use of the detection method. A nano-plasma enhanced scattering (nPES) detection technology can be used to quantify exosomes in serum, an exosome extracting process is omitted, the characteristic antigen of the exosomes is used as a target, and the antigen and a corresponding antibody carrying gold nanoparticles form an antigen-antibody complex in order to obtain exosomes, and the amount of the exosomes is reflected by using the light radiation principle of the gold nanoparticles. The Glypican-1 is a pancreatic cancer-derived exosome biomarker, and the content of Glypican-1 positive exosomes in blood plasma has specific specificity even in early pancreatic cancer, so the exosome content index can be used to diagnose the pancreatic cancer, and the exosome level is closely related to the staging and progression of pancreatic cancer patients. Experiments prove that the method using the nPES detection technology to detect the content of the Glypican-1 exosomes in the serum is concise and accurate, and has better sensitivity and specificity than CA19-9 in the diagnosis of the pancreatic cancer.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV
Compositions and methods for inhibiting growth of smad4-deficient cancers
The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment / prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and / or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.
Owner:BIOGEN MA INC
Treatments for cancer
InactiveUS20050271670A1Reducing pancreatic tumor expansionDecrease in cell survivalMicrobiological testing/measurementGenetic material ingredientsPancreatic tumorCTGF
The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents.
Owner:FIBROGEN INC
Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
InactiveUS20100111969A1High expressionHigh incidenceBiological material analysisImmunoglobulins against cytokines/lymphokines/interferonsIl 4 receptorEphA Receptors
Owner:APOGENIX AG
Method for establishing pancreatic cancer model
ActiveCN105132463AHigh simulationEfficient methodGenetic engineeringFermentationWilms' tumorTumor suppressor gene
The invention relates to a method for establishing a pancreatic cancer model, and belongs to the technical field of the establishment of an animal model. According to the method, a slow virus for over-expressing one cancer gene and simultaneous knocking down two cancer suppressor genes is constructed according to cancer genes and cancer suppressor genes having the maximum mutation rate in human pancreatic cancer in TCGA database, and the slow virus is applied to the pancreas head of a tree shrew through orthotopic injection so as to induce pancreatic cancer of the tree shrew; and specifically, the method comprises the following steps: (1) construction of a slow virus vector; (2) virus packaging, titre determination and in vitro verification; (3) virus injection; and (4) monitoring and pathological investigation of the tree shrew. The method disclosed by the invention has the advantages that the method is short in inducing cycle, high and stable in morbidity, and simple and convenient in operation, and is capable of rapidly and effectively establishing a tree shrew pancreatic cancer model for simulating the genetic mechanism of human pancreatic cancer to the greatest extent; and the pancreatic cancer model is applicable to the research of the pathogenesis of human pancreatic cancer, the exploration of cancer therapy targets and the development of novel antineoplastic drugs, so as to offer a reference for the treatment of human pancreatic cancer.
Owner:成都豆麦科技有限公司
Method for detecting pancreatic tumor, antibody, and pancreatic tumor detection kit
ActiveCN105637366AEasy to measureImprove throughputImmunoglobulins against animals/humansBiological material analysisSingular value decompositionAntiendomysial antibodies
A method, system and storage device are generally directed to determining for each of a plurality of data points, a neighborhood of data points about each such data point. For each such neighborhood of data points, a projection set of polynomials is generated based on candidate polynomials. The projection set of polynomials evaluated on the neighborhood of data points is subtracted from the plurality of candidate polynomials evaluated on the neighborhood of data points to generate a subtraction matrix of evaluated resulting polynomials. The singular value decomposition of the subtraction matrix is then computed. The resulting polynomials are clustered into multiple clusters and then partitioned based on a threshold.
Owner:TORAY IND INC +1
Compositions and methods for inhibiting growth of smad4-deficient cancers
The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment / prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and / or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.
Owner:BIOGEN MA INC
Method for establishing pancreatic cancer model in wild-type adult mouse through lentiviruses
The invention discloses a method for establishing a pancreatic cancer model in a wild-type adult mouse through lentiviruses. The method comprises lentiviral vector construction, virus packaging, titerdetermination and in-vitro verification, virus injection, and pathological identification. The method comprises selecting an oncogene Kras with the highest variation rate of the human pancreatic cancer and cancer suppressor genes of Tp53, Cdkn2a and Cdkn2b, overexpressing the oncogene KrasG12D in the same lentiviral vectors, simultaneously, knocking down Tp53, Cdkn2a and Cdkn2b through shRNA, carrying out virus injection, and after 40 days, detecting significant pancreatic tumors in the adult mouse which is killed by the pancreatic cancer. The method has a short induction period and high andstable incidence, is easy to operate and fast builds the adult mouse pancreatic cancer model. The pancreatic cancer model simulates the genetic mechanism of human pancreatic cancer to the maximum extent, can be used to study the pathogenesis of human pancreatic cancer and the screening of new therapeutic drugs and therapeutic target points and provides a reference for the treatment on human pancreatic cancer.
Owner:成都豆麦科技有限公司
Method based on combination of gold nanoclusters and NGF siRNA for treating pancreatic cancer
ActiveCN107362370AImprove stabilityProlong circulation time in the bodyPowder deliveryOrganic active ingredientsMedicineWilms' tumor
The invention provides a NGF siRNA-combined gold nanocluster. The NGF siRNA-combined gold nanocluster comprises a gold nanocluster body and NGF siRNA which are combined through the electrostatic adsorption effect. The invention further provides a preparation method of the NGF siRNA-combined gold nanocluster, a drug composition and a reagent box containing the NGF siRNA-combined gold nanocluster and application of the NGF siRNA-combined gold nanocluster in preparation of drugs used for preventing and / or treating cancer. According to the NGF siRNA-combined gold nanocluster, the siRNA stability can be improved, the body-interior circulation time is prolonged, the target ability of pancreatic tumor is improved, the mum effect of NGF is improved, and the anti-tumor treating effect of pancreatic cancer is improved; and the preparation method is simple, the reaction condition is mild, and a new pathway is developed for treating of the pancreatic cancer.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Method for culturing pancreatic cancer cell under anaerobic environment
InactiveCN106947739AImprove accuracyCulture processTumor/cancer cellsCancer cellPancreatic cancer cell
The invention discloses a method for culturing pancreatic cancer cells under anaerobic environment. The method comprises the following step: by simulating a true growing environment of pancreatic cancer in a human body, culturing three common pancreatic cancer cells under anaerobic environment, wherein the cancer cells obtained through culturing are more closer to those growing under the true conditions, thus providing good base materials for studying the experiment accuracy and leading the acquired cancer cell material to have true persuasion in the following scientific experiments.
Owner:孙诚谊
Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
InactiveUS20050245445A1Reduce severityTumor rejection antigen precursorsPeptide/protein ingredientsPancreatic tumorLesion
The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
Owner:BURNHAM INST FOR MEDICAL RES +1
Pancreatic tumor image segmentation method and system based on reinforcement learning and attention
ActiveCN114663431ADoes not involve deliveryAvoid Segmentation Inaccuracy ProblemsImage enhancementImage analysisRadiologyImage segmentation
The invention discloses a pancreatic tumor image segmentation method and system based on reinforcement learning and attention, and the method comprises the steps: extracting an ROI region through a three-dimensional coarse segmentation model, segmenting an ROI region image and an original image into a 2D image along a z axis, selecting two reference layers from the segmented ROI region image through a reinforcement learning network, and carrying out the segmentation of the two reference layers, selecting a segmentation layer from the segmented original image, jointly inputting the segmented original image and the segmented original image into a two-dimensional fine segmentation model with a cross attention feature fusion module, and enabling segmentation features to perform information interaction in the segmentation layer and a reference layer by using the cross attention feature fusion module between the layers to obtain a segmentation result of the pancreatic tumor; according to the method, related information of non-adjacent 2D images is learned by using a cross attention mechanism, so that the limitation that a 2D neural network cannot accurately position a tumor by using interlayer information is avoided, and the problem of inaccurate tumor segmentation caused by redundancy and interference of 3D data information of a 3D neural network is also avoided.
Owner:ZHEJIANG UNIV
Pancreatic tumor image segmentation method based on dense connection network transfer learning
PendingCN113706486AEasy to learnImprove performanceImage enhancementImage analysisPET-CTFeature extraction
The invention discloses a pancreatic tumor image segmentation method based on dense connection network transfer learning, and the method comprises the steps: obtaining PET (positron emission computed tomography) and MRI (magnetic resonance imaging), carrying out the preprocessing of the PET and MRI, and dividing the PET and MRI into a training set and a test set; constructing a segmentation network, and training the segmentation network by using a PET training data set to obtain a network parameter W1 after one-time training; setting an initial parameter of a feature extraction module in the segmentation network as a value of a corresponding module in W1 by using a migration strategy, randomly initializing parameters of other modules, and retraining the segmentation network by using an MRI image training set to obtain a secondarily trained network parameter W2; and inputting the MRI test set into a segmentation network taking W2 as a network parameter to obtain a segmentation result. The method improves the performance of MRI image segmentation, solves the problem that a network is difficult to train for a small data set in the prior art, and can be used for assisting a doctor to complete automatic target region sketching before pancreatic tumor treatment.
Owner:XIDIAN UNIV
Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK-lipopeptide, at least two co-lipids, therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).
Owner:COUNCIL OF SCI & IND RES +1
Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
InactiveUS7598341B2Reduce severityTumor rejection antigen precursorsPeptide/protein ingredientsPancreatic tumorLesion
The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
Owner:BURNHAM INST FOR MEDICAL RES +1
Pathways underlying pancreatic tumorigenesis and an hereditary pancreatic cancer gene
There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ~one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications.; Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70 % to 100 % of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Tumor cell preparation device for constructing human pancreatic cancer rabbit pancreatic head xenograft tumor model
ActiveCN104726333BReduce usageReduce stepsBioreactor/fermenter combinationsBiological substance pretreatmentsAbnormal tissue growthEngineering
Owner:QIQIHAR MEDICAL UNIVERSITY
Chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 and purpose thereof
InactiveCN109467605AMild release responseEnsure safetyAntibody mimetics/scaffoldsMammal material medical ingredientsHeavy chainAntigen receptors
The invention discloses a chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 and a purpose thereof. The chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 comprises an intracellular second transduction domain DAP12, T2A, a CD8alpha signal peptide, anti-human MSLN monoclonal antibody ss1 light chain and heavy chain variable regions MSLN scFv and an intracellular first transduction domain which are connected with each other in series. The chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 disclosed by the invention is used for modifying T lymphocytes; and the modified T cells (CAR-T cells) can be used for treating MSLN positive malignant solid tumors. In a malignant solid tumor killing test, the killing ability of the CAR-T cells to pancreatic tumor cells is obviously enhanced, and good safety and antineoplastic activity are shown in clinical application.
Owner:NANJING CART MEDICAL TECH LTD
Drug delivery system with tumor microenvironment adjustment and targeting function and application thereof in pharmacy
InactiveCN110898033ALow toxicityReduce secretionOrganic active ingredientsMacromolecular non-active ingredientsTumor targetOfficinal
The invention belongs to the field of screening of effective components of traditional Chinese medicines and preparations of the effective components, and relates to a drug delivery system with tumormicroenvironment adjustment and a targeting function and application thereof in pharmacy, in particular to application in pancreatic tumor treatment. The invention discloses a nano delivery system. Nanoparticles which are constructed from a medical polymer polylactic acid material, have good biocompatibility and biodegradability and have the effects of regulating a tumor microenvironment and increasing blood perfusion are adopted, a section of functional polypeptide CGKRK is covalently bonded to the surface, the CGKRK can target heparan sulfate which is highly-expressed in the tumor microenvironment, and the tumor targeting property is improved; and natural drug monomers are physically entrapped in hydrophobic cores of the nanoparticles through an emulsifying solvent evaporation method, sothat the solubility of the drug is improved, and the in-vivo circulation time of the drug is prolonged. The established drug-loaded nano system can inhibit the excessive activation of CAFs, reduce the proportion of M2 macrophages, effectively improve the tumor microenvironment and increase the accumulation of the drug at the tumor site.
Owner:FUDAN UNIV
Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
Owner:MARATHON PHARMA LLC
Monoacylglycerols and fat-soluble nutrients for use in the treatment of maldigestion
InactiveCN105658216ASolve the problem of nutritional effects of indigestion)Effective intakeHydroxy compound active ingredientsMetabolism disorderNutritional deficiencyPhysiology
Compositions comprising monoacylglycerols (MAG), such as sn-1(3) MAG, and further comprising fat-soluble nutrients, such as fat-soluble vitamins and carotenoids, are administered to an individual having or at risk of maldigestion, such as maldigestion associated with chronic pancreatitis, cystic fibrosis, diabetes, pancreatic duct obstruction, a pancreatic tumor, or Shwachman-Diamondsyndrome (SDS). The compositions and the methods of using the compositions enhance absorption of fatty acids and the fat-soluble nutrients to address nutritional deficiencies due to maldigestion.
Owner:NESTEC SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com